Phase II study of Amrubicin in patients with Small-Cell Lung Cancer that is refractory or relapsed within 90 days of completing previous treatment (JCOG0901)
Phase 2
- Conditions
- Refractory relpased small-cell lung cancer
- Registration Number
- JPRN-UMIN000002763
- Lead Sponsor
- Japan Clinical Oncology Group(JCOG)
- Brief Summary
See the datails via "URL releasing results" above. Also the details can be seen in the JCOG website: http://www.jcog.jp/en/trials/index.html
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
Not provided
Exclusion Criteria
1) active concomitant malignancy 2) active infection 3) fever 4) pregnancy or lactation 5) serious psychiatric illness 6) steroid treatment 7) massive pleural or pericardial effusion 8) symptomatic brain metastasis 9) interstitial pneumonia or severe pulmonary emphysema 10) ileus 11) myocardial infarction within 6 months or unstable angina 12) uncontrollable hypertension 13) uncontrollable diabetes mellitus
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method response rate
- Secondary Outcome Measures
Name Time Method overall survival, progression-free survival, adverse events